View More Recent Stories

Mar 18, 2025 04:04AM Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 23, 2024 04:07PM Abivax (ABVX) Announces Board Changes
Dec 17, 2024 10:26AM Piper Sandler Reiterates Overweight Rating on Abivax (ABVX) Following New IBD Surveys
Dec 4, 2024 03:20AM JMP Securities Starts Abivax (ABVX) at Market Outperform
Nov 19, 2024 04:31PM Abivax (ABVX) Announces $150M ATM Program
Nov 13, 2024 04:03PM Abivax (ABVX) Appoints Mark Stenhouse as Board Observer
Oct 3, 2024 06:00AM Abivax (ABVX) Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod
Sep 30, 2024 06:12AM Guggenheim Reiterates Buy Rating on Abivax (ABVX)
Sep 26, 2024 12:11PM Piper Sandler Reiterates Overweight Rating on Abivax (ABVX)
Sep 26, 2024 08:21AM BTIG Reiterates Buy Rating on Abivax (ABVX)
Sep 25, 2024 04:01PM Abivax (ABVX) Provides Update on Ulcerative Colitis Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod
Sep 24, 2024 07:42AM Piper Sandler Reiterates Overweight Rating on Abbvie (ABBV)
Sep 10, 2024 07:45AM Piper Sandler Reiterates Overweight Rating on Abivax (ABVX)
Jul 16, 2024 05:53AM Piper Sandler Reiterates Overweight Rating on Abivax (ABVX)
Jul 15, 2024 04:00PM Abivax (ABVX) Provides Operational and Key Program Update
View More Recent Stories